These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 15791568

  • 1. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers.
    Wilczynski SP, Chen YY, Chen W, Howell SB, Shively JE, Alberts DS.
    Hum Pathol; 2005 Mar; 36(3):242-9. PubMed ID: 15791568
    [Abstract] [Full Text] [Related]

  • 2. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
    Schmandt RE, Broaddus R, Lu KH, Shvartsman H, Thornton A, Malpica A, Sun C, Bodurka DC, Gershenson DM.
    Cancer; 2003 Aug 15; 98(4):758-64. PubMed ID: 12910520
    [Abstract] [Full Text] [Related]

  • 3. Expression of c-kit and platelet-derived growth factor receptors in ovarian granulosa cell tumors.
    Rocconi RP, Matthews KS, Kimball KJ, Conner MG, Baker AC, Barnes MN.
    Reprod Sci; 2008 Sep 15; 15(7):673-7. PubMed ID: 18492696
    [Abstract] [Full Text] [Related]

  • 4. Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours: is there a role for tyrosine kinase inhibitors in c-kit-negative desmoid tumours?
    Liegl B, Leithner A, Bauernhofer T, Windhager R, Guelly C, Regauer S, Beham A.
    Histopathology; 2006 Dec 15; 49(6):576-81. PubMed ID: 17163842
    [Abstract] [Full Text] [Related]

  • 5. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas.
    Tamborini E, Miselli F, Negri T, Lagonigro MS, Staurengo S, Dagrada GP, Stacchiotti S, Pastore E, Gronchi A, Perrone F, Carbone A, Pierotti MA, Casali PG, Pilotti S.
    Clin Cancer Res; 2006 Dec 01; 12(23):6920-8. PubMed ID: 17145809
    [Abstract] [Full Text] [Related]

  • 6. Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors.
    Welin S, Fjällskog ML, Saras J, Eriksson B, Janson ET.
    Neuroendocrinology; 2006 Dec 01; 84(1):42-8. PubMed ID: 17047316
    [Abstract] [Full Text] [Related]

  • 7. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors.
    Fjällskog ML, Lejonklou MH, Oberg KE, Eriksson BK, Janson ET.
    Clin Cancer Res; 2003 Apr 01; 9(4):1469-73. PubMed ID: 12684421
    [Abstract] [Full Text] [Related]

  • 8. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
    Slomovitz BM, Broaddus RR, Schmandt R, Wu W, Oh JC, Ramondetta LM, Burke TW, Gershenson DM, Lu KH.
    Gynecol Oncol; 2004 Oct 01; 95(1):32-6. PubMed ID: 15385107
    [Abstract] [Full Text] [Related]

  • 9. Tyrosine kinase receptor status in endometrial stromal sarcoma: an immunohistochemical and genetic-molecular analysis.
    Cossu-Rocca P, Contini M, Uras MG, Muroni MR, Pili F, Carru C, Bosincu L, Massarelli G, Nogales FF, De Miglio MR.
    Int J Gynecol Pathol; 2012 Nov 01; 31(6):570-9. PubMed ID: 23018215
    [Abstract] [Full Text] [Related]

  • 10. Expression of platelet-derived growth factor receptor in low-grade endometrial stromal sarcomas in the absence of activating mutations.
    Liegl B, Gülly C, Reich O, Nogales FF, Beham A, Regauer S.
    Histopathology; 2007 Mar 01; 50(4):448-52. PubMed ID: 17448020
    [Abstract] [Full Text] [Related]

  • 11. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
    Do I, Araujo ES, Kalil RK, Bacchini P, Bertoni F, Unni KK, Park YK.
    Pathol Res Pract; 2007 Mar 01; 203(3):127-34. PubMed ID: 17298867
    [Abstract] [Full Text] [Related]

  • 12. Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.
    Zheng S, Chen LR, Wang HJ, Chen SZ.
    Hepatogastroenterology; 2007 Dec 01; 54(80):2285-90. PubMed ID: 18265649
    [Abstract] [Full Text] [Related]

  • 13. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
    Raafat A, Zoltan-Jones A, Strizzi L, Bargo S, Kimura K, Salomon D, Callahan R.
    Oncogene; 2007 Feb 01; 26(5):662-72. PubMed ID: 16878155
    [Abstract] [Full Text] [Related]

  • 14. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
    Basciani S, Brama M, Mariani S, De Luca G, Arizzi M, Vesci L, Pisano C, Dolci S, Spera G, Gnessi L.
    Cancer Res; 2005 Mar 01; 65(5):1897-903. PubMed ID: 15753388
    [Abstract] [Full Text] [Related]

  • 15. PDGFR expression in differential diagnosis between KIT-negative gastrointestinal stromal tumours and other primary soft-tissue tumours of the gastrointestinal tract.
    Rossi G, Valli R, Bertolini F, Marchioni A, Cavazza A, Mucciarini C, Migaldi M, Federico M, Trentini GP, Sgambato A.
    Histopathology; 2005 May 01; 46(5):522-31. PubMed ID: 15842634
    [Abstract] [Full Text] [Related]

  • 16. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
    Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, Byrnes C, Sanders K, Sosman JA.
    Cancer; 2006 May 01; 106(9):2005-11. PubMed ID: 16565971
    [Abstract] [Full Text] [Related]

  • 17. PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma.
    Lagonigro MS, Tamborini E, Negri T, Staurengo S, Dagrada GP, Miselli F, Gabanti E, Greco A, Casali PG, Carbone A, Pierotti MA, Pilotti S.
    J Pathol; 2006 Apr 01; 208(5):615-23. PubMed ID: 16470538
    [Abstract] [Full Text] [Related]

  • 18. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms.
    Henriksen R, Funa K, Wilander E, Bäckström T, Ridderheim M, Oberg K.
    Cancer Res; 1993 Oct 01; 53(19):4550-4. PubMed ID: 8402626
    [Abstract] [Full Text] [Related]

  • 19. PDGFR-alpha as a potential therapeutic target in uterine sarcomas.
    Adams SF, Hickson JA, Hutto JY, Montag AG, Lengyel E, Yamada SD.
    Gynecol Oncol; 2007 Mar 01; 104(3):524-8. PubMed ID: 17049587
    [Abstract] [Full Text] [Related]

  • 20. Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer.
    Matei D, Emerson RE, Lai YC, Baldridge LA, Rao J, Yiannoutsos C, Donner DD.
    Oncogene; 2006 Mar 30; 25(14):2060-9. PubMed ID: 16331269
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.